放疗对抗肿瘤免疫的影响：从基础到临床

doi:10.3760/cma.j.cn371439-20240727-00038

摘要/Abstract

摘要：

放疗在肿瘤的治疗中占据重要地位，除可直接引起肿瘤细胞DNA损伤、诱导细胞凋亡外，还参与调节全身免疫状态。越来越多的证据表明，放疗可重塑肿瘤免疫微环境（TIME），逆转免疫抑制状态，从而有利于增强抗肿瘤作用，并在与免疫检查点抑制剂联合应用时表现出更强的免疫反应和治疗获益。以肺癌为例探讨放疗对TIME及抗肿瘤免疫的影响和可能机制，可为优化肺癌治疗策略提供科学依据。

关键词: 放射疗法, 肺肿瘤, 肿瘤微环境, 免疫疗法, 免疫调节

Abstract:

Radiotherapy is a crucial component of the treatment of tumors. In addition to directly causing DNA damage in tumor cells and inducing cell apoptosis，radiotherapy is also involved in the regulation of systemic immune status. Increasing evidence indicates that radiotherapy can remodel the tumor immune microenvironment （TIME） and reverse the immunosuppressive state，thereby enhancing anti-tumor effects and demonstrating stronger immune responses and therapeutic benefits when combined with immune checkpoint inhibitors. Taking lung cancer as an example to explore the impacts and potential mechanisms of radiotherapy on the TIME and anti-tumor immunity，which can provide a scientific basis for optimizing the treatment strategies of lung cancer.

Key words: Radiotherapy, Lung neoplasms, Tumor microenvironment, Immunotherapy, Immunomodulation

文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.

Wen Yingmei, Xia Jinxiong, Wang Yuanyuan, Yao Yi. Impacts of radiotherapy on anti-tumor immunity：a comprehensive review from the fundamental to the clinical[J]. Journal of International Oncology, 2025, 52(4): 231-236.

参考文献 51

[1]	Guo S, Yao Y, Tang Y, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 205. DOI: 10.1038/s41392-023-01462-z.
[2]	Hannon G, Lesch ML, Gerber SA. Harnessing the immunological effects of radiation to improve immunotherapies in cancer[J]. Int J Mol Sci, 2023, 24(8): 7359. DOI: 10.3390/ijms24087359.
[3]	McGee HM, Marciscano AE, Campbell AM, et al. Parallels between the antiviral state and the irradiated state[J]. J Natl Cancer Inst, 2021, 113(8): 969-979. DOI: 10.1093/jnci/djaa190. pmid: 33252657
[4]	Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises[J]. Mol Cancer, 2023, 22(1): 40. DOI: 10.1186/s12943-023-01740-y.
[5]	Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5): 467-475. DOI: 10.1016/s2213-2600(20)30391-x.
[6]	Zhu M, Yang M, Zhang J, et al. Immunogenic cell death induction by ionizing radiation[J]. Front Immunol, 2021, 12: 705361. DOI: 10.3389/fimmu.2021.705361.
[7]	Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer, 2021, 21(5): 298-312. DOI: 10.1038/s41568-021-00339-z. pmid: 33750922
[8]	Galluzzi L, Aryankalayil MJ, Coleman CN, et al. Emerging evidence for adapting radiotherapy to immunotherapy[J]. Nat Rev Clin Oncol, 2023, 20(8): 543-557. DOI: 10.1038/s41571-023-00782-x. pmid: 37280366
[9]	Mirestean CC, Iancu RI, Iancu DT. Immunotherapy and radiotherapy as an antitumoral long-range weapon—a partnership with unsolved challenges: dose, fractionation, volumes, therapeutic sequence[J]. Curr Oncol, 2022, 29(10): 7388-7395. DOI: 10.3390/curroncol29100580.
[10]	Zhu S, Wang Y, Tang J, et al. Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment[J]. Front Immunol, 2022, 13: 1074477. DOI: 10.3389/fimmu.2022.1074477.
[11]	Oweida AJ, Darragh L, Phan A, et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer[J]. J Natl Cancer Inst, 2019, 111(12): 1339-1349. DOI: 10.1093/jnci/djz036. pmid: 30863843
[12]	Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Signal Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
[13]	Song CW, Kim H, Cho H, et al. HIF-1α inhibition improves anti-tumor immunity and promotes the efficacy of stereotactic ablative radiotherapy (SABR)[J]. Cancers (Basel), 2022, 14(13): 3273. DOI: 10.3390/cancers14133273.
[14]	Craig DJ, Nanavaty NS, Devanaboyina M, et al. The abscopal effect of radiation therapy[J]. Future Oncol, 2021, 17(13): 1683-1694. DOI: 10.2217/fon-2020-0994.
[15]	Mondini M, Levy A, Meziani L, et al. Radiotherapy-immunotherapy combinations-perspectives and challenges[J]. Mol Oncol, 2020, 14(7): 1529-1537. DOI: 10.1002/1878-0261.12658.
[16]	Chen D, Menon H, Verma V, et al. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials[J]. J Immunother Cancer, 2020, 8(1): e000492. DOI: 10.1136/jitc-2019-000492corr1.
[17]	Zhai D, An D, Wan C, et al. Radiotherapy: Brightness and darkness in the era of immunotherapy[J]. Transl Oncol, 2022, 19: 101366. DOI: 10.1016/j.tranon.2022.101366.
[18]	Zhao X, Hu S, Zeng L, et al. Irradiation combined with PD-L1^-/- and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation[J]. iScience, 2022, 25(8): 104690. DOI: 10.1016/j.isci.2022.104690.
[19]	van der Woude LL, Gorris MAJ, Wortel IMN, et al. Tumor micro-environment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination[J]. J Immunother Cancer, 2022, 10(10): e005248. DOI: 10.1136/jitc-2022-005248.
[20]	Benna M, Guy JB, Bosacki C, et al. Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?[J]. Br J Radiol, 2020, 93(1109): 20190147. DOI: 10.1259/bjr.20190147.
[21]	Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase Ⅰ KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28): 2518-2527. DOI: 10.1200/JCO.19.00934.
[22]	Zhou X, Zhou L, Yao Z, et al. Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-naïve stage Ⅳ PD-L1⁺ non-small cell lung cancer patients[J]. Clin Cancer Res, 2023, 29(20): 4098-4108. DOI: 10.1158/1078-0432.Ccr-23-0315.
[23]	Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 824-835. DOI: 10.1016/s1470-2045(21)00149-2.
[24]	Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial[J]. Lancet, 2023, 402(10405): 871-881. DOI: 10.1016/s0140-6736(23)01384-3. pmid: 37478883
[25]	Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282. DOI: 10.1001/jamaoncol.2019.1478.
[26]	Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(12): 1301-1311. DOI: 10.1200/JCO.21.01308. pmid: 35108059
[27]	Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 209-219. DOI: 10.1016/s1470-2045(21)00630-6.
[28]	Tian S, Switchenko JM, Buchwald ZS, et al. Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 304-313. DOI: 10.1016/j.ijrobp.2019.12.030.
[29]	Liu Z, Xu T, Chang P, et al. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: a systematic review and meta-analysis[J]. Front Pharmacol, 2023, 14: 1064227. DOI: 10.3389/fphar.2023.1064227.
[30]	Donlon NE, Power R, Hayes C, et al. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity[J]. Cancer Lett, 2021, 502: 84-96. DOI: 10.1016/j.canlet.2020.12.045. pmid: 33450360
[31]	Zhao X, Li J, Zheng L, et al. Immune response on optimal timing and fractionation dose for hypofractionated radiotherapy in non-small-cell lung cancer[J]. Front Mol Biosci, 2022, 9: 786864. DOI: 10.3389/fmolb.2022.786864.
[32]	Gkika E, Firat E, Adebahr S, et al. Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer[J]. NPJ Precis Oncol, 2023, 7(1): 24. DOI: 10.1038/s41698-023-00358-z.
[33]	Herrera FG, Romero P, Coukos G. Lighting up the tumor fire with low-dose irradiation[J]. Trends Immunol, 2022, 43(3): 173-179. DOI: 10.1016/j.it.2022.01.006. pmid: 35105519
[34]	Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma[J]. J Immunother Cancer, 2020, 8(2): e000537. DOI: 10.1136/jitc-2020-000537.
[35]	Patel RR, He K, Barsoumian HB, et al. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase Ⅱ trial[J]. Radiother Oncol, 2021, 162: 60-67. DOI: 10.1016/j.radonc.2021.06.037.
[36]	Novikov SN, Baldueva IA, Zozulya AY, et al. Peripheral blood lymphocyte changes after stereotactic ablative body radiotherapy to lung or liver metastases in patients with oligometastatic cancers[J]. Radiat Oncol J, 2023, 41(1): 23-31. DOI: 10.3857/roj.2022.00521. pmid: 37013415
[37]	Wu M, Liu J, Wu S, et al. Systemic immune activation and responses of irradiation to different metastatic sites combined with immunotherapy in advanced non-small cell lung cancer[J]. Front Immunol, 2021, 12: 803247. DOI: 10.3389/fimmu.2021.803247.
[38]	Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: from "systemic" to "multisite"[J]. Clin Cancer Res, 2020, 26(12): 2777-2782. DOI: 10.1158/1078-0432.CCR-19-2034. pmid: 32047000
[39]	Cantor DJ, Davis C, Ciunci C, et al. Brief report: long-term follow-up of adjuvant pembrolizumab after locally ablative therapy for oligometastatic NSCLC[J]. JTO Clin Res Rep, 2024, 5(6): 100667. DOI: 10.1016/j.jtocrr.2024.100667.
[40]	Billing DL, Rimner A. Results of radiation therapy as local ablative therapy for oligometastatic non-small cell lung cancer[J]. Cancers (Basel), 2021, 13(22): 5773. DOI: 10.3390/cancers13225773.
[41]	Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051-2058. DOI: 10.1016/s0140-6736(18)32487-5. pmid: 30982687
[42]	Scoccianti S, Olmetto E, Pinzi V, et al. Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO[J]. Neuro Oncol, 2021, 23(10): 1750-1764. DOI: 10.1093/neuonc/noab129.
[43]	Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC—an update from the PACIFIC trial[J]. J Thorac Oncol, 2021, 16(5): 860-867. DOI: 10.1016/j.jtho.2020.12.015. pmid: 33476803
[44]	Lin SH, Lin Y, Yao L, et al. Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC[J]. J Thorac Oncol, 2020, 15(2): 248-257. DOI: 10.1016/j.jtho.2019.10.024.
[45]	Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer—the ETOP NICOLAS trial[J]. Lung Cancer, 2019, 133: 83-87. DOI: 10.1016/j.lungcan.2019.05.001. pmid: 31200833
[46]	Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial[J]. JAMA Oncol, 2021, 7(9): 1-9. DOI: 10.1001/jamaoncol.2021.2301.
[47]	Xing P, Yang J, Kong Y, et al. A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors[J]. J Clin Oncol, 2022, 40(16_suppl): 2609. DOI: 10.1200/JCO.2022.40.16_suppl.2609.
[48]	Kong Y, Chen R, Xu M, et al. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)[J]. BMJ Open, 2024, 14(3): e075642. DOI: 10.1136/bmjopen-2023-075642.
[49]	Jabbour SK, Cho BC, Bria E, et al. Rationale and design of the phase Ⅲ KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage Ⅲ non-small-cell lung cancer[J]. Clin Lung Cancer, 2022, 23(6): e342-e346. DOI: 10.1016/j.cllc.2022.04.003. pmid: 35618629
[50]	De Ruysscher D, Ramalingam S, Urbanic J, et al. CheckMate 73L: a phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage Ⅲ non-small-cell lung cancer[J]. Clin Lung Cancer, 2022, 23(3): e264-e268. DOI: 10.1016/j.cllc.2021.07.005.
[51]	Xing L, Yu J, Peters S, et al. 167TiP AdvanTIG-301: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC[J]. Ann Oncol, 2021, 32(Suppl 7): S1455. DOI: 10.1016/j.annonc.2021.10.186.